Trial Profile
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Miravirsen (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2015 New trial record